

References

I-127

1. Blincyto (blinatumomab) [package insert]. Thousand Oaks, CA. Amgen Inc. Revised 03/2018.
2. MICROMEDEX®SOLUTIONS Compendia. Blincyto (blinatumomab). 2018.
3. Clinical Trials.gov. U.S. National Institutes of Health. Study of the BiTE® blinatumomab (MT103) in adult patients with relapsed/refractory B-precursor Acute Lymphoblastic Leukemia (ALL) *ClinicalTrials.gov* Identifier: NCT01209286.
4. National Comprehensive Cancer Network (NCCN). Blinatumomab. *NCCN Drug & Biologics Compendium®*, 2018.
5. Topp M, Gökbuget N, Bargou R, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. *J Clin Oncol*. 2014;32(36):4134-4140.
6. Sanford M. Blinatumomab: First global approval. *Drugs*. 2015;75(3):321-327.
7. Wu J, Fu J, Zhang M, et al.. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. *J Hematol Oncol*. 2015;8:104.
8. Köhnke T, Krupka C, Tischer J, et al. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. *J Hematol Oncol*. 2015;8(1):111.
9. Blinatumomab: A novel, bispecific, T-cell engaging antibody. *AM J Health Systm Pharm*. 2016;73(1):e6-e13.
10. Gökbuget N, Zugmaier G, Bargou R, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. *Haematologica*. 2017;102(4):e132-e135.
11. Von Stackelberg A, Locatelli F, Gore L, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Clin Oncol*. 2016;34(36):4381-4389.
12. Le Jeune C, Thomas X. Potential for bispecific T-cell engagers: Role of blinatumomab in acute lymphoblastic leukemia. *Drug Design, Development And Therapy* 2016;10:757-765.
13. Barlev A, Lin VW, Katz A, Hu K. Estimating long-term survival of adults with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia treated with blinatumomab using historical data. *Adv Ther*. 2017;34:148-155.
14. Martinelli G, Boissel N, Chevallier P, Ottmann O, Gokbuget N, Topp M, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. *Journal of Clinical Oncology*. 2017;35(16):1795-1802.
15. Stackelberg A, Locatelli F, Zugmaier G, Hangretinger R, Trippett TM, Rizzari C, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. *Journal of Clinica Oncology*. 2016;34(36):4381-4389.